Hyperfine Inc. Class A Common Stock (HYPR)
Stock · NASDAQ · Health Care
$0.7441as of 10/16/2026
Price chart
Active signals
HYPR Signal Track Record
How signals performed across all stocks →What HYPR's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 44 | -1.5% | 48% | October 8, 2026 |
| Bollinger Band Breakout | 22 | -2.8% | 36% | October 1, 2026 |
| Bollinger Band Breakdown | 18 | -1.4% | 50% | July 8, 2026 |
| 200-Day Moving Average TouchActive now | 14 | -1.9% | 36% | July 6, 2026 |
| Any 20-session window (baseline) | -2.7% | 43% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About HYPR
Hyperfine, Inc., a health technology company, engages in the production, supply, service, and commercialization of magnetic resonance imaging (MRI) products. Its Swoop Portable MR Imaging System produces images at a lower magnetic field strength than conventional MRI scanners. The company also offers support and technical assistance services, as well as Hyperfine Image Viewer, a cloud picture archiving and communicat…
- Sector
- Health Care
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Employees
- 102
- Website
- hyperfinemri.com/
Fundamentals
- 1-day range
- $0.761$0.8122
- Market cap
- $97.48M
- P/E (trailing)
- —
- P/E (forward)
- -2.44
- EPS (trailing)
- $-0.38
- Dividend yield
- —
- Beta
- 1.51
- Avg. volume
- 760.1K
How Hyperfine Inc. Class A Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 18, 2026 · via SEC EDGAR / Finnhub
Forecasts
3 analyst ratings
Hyperfine Inc. Class A Common Stock Competitors
Chosen by industry and closest market cap.
- HYPRHyperfine Inc. Class A Common Stock$0.755▼ 3.21%Market cap $97.48MP/E —$0.7536$2.22
- HSDTSolana Company Class A Common Stock (DE)$2.24▼ 4.68%Market cap $98.09MP/E —$1.19$16.81
- OMOutset Medical Inc. Common Stock$3.94▼ 3.43%Market cap $96.39MP/E —$2.84$15.94
- NRXSNeuraxis Inc. Common Stock$7.7▼ 0.52%Market cap $86.47MP/E —$2.21$9.33
- VANIVivani Medical Inc. Common Stock (DE)$1.12▼ 2.61%Market cap $117.28MP/E —$0.9227$1.92
- STEXStreamex Corp. Common Stock$0.374▼ 8.33%Market cap $75.35MP/E —$0.3876$6.5
- STXSStereotaxis Inc. Common Stock$1.01▼ 3.81%Market cap $133.19MP/E —$1.02$3.2
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| HYPR Hyperfine Inc. Class A Common Stock | $97.48M | — | $0.755 | ▼ 3.21% | $0.7536$2.22 |
| HSDT Solana Company Class A Common Stock (DE) | $98.09M | — | $2.24 | ▼ 4.68% | $1.19$16.81 |
| OM Outset Medical Inc. Common Stock | $96.39M | — | $3.94 | ▼ 3.43% | $2.84$15.94 |
| NRXS Neuraxis Inc. Common Stock | $86.47M | — | $7.7 | ▼ 0.52% | $2.21$9.33 |
| VANI Vivani Medical Inc. Common Stock (DE) | $117.28M | — | $1.12 | ▼ 2.61% | $0.9227$1.92 |
| STEX Streamex Corp. Common Stock | $75.35M | — | $0.374 | ▼ 8.33% | $0.3876$6.5 |
| STXS Stereotaxis Inc. Common Stock | $133.19M | — | $1.01 | ▼ 3.81% | $1.02$3.2 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Full Transcript: Hyperfine Q2 2026 Earnings Callbenzinga · 10/12/2026
- Hyperfine Reports Record Preliminary Q3 Revenue of $6 Million, Up 53% SequentiallyYahoo · 10/8/2026
- Hyperfine Reports Record Preliminary Third Quarter Revenue of Approximately $6.0 Million & Reaffirms Full Year 2026 Revenue Outlook of Approximately $20 to $22 MillionYahoo · 10/8/2026
- Hyperfine, Inc. to Announce Third Quarter 2026 Financial Results on November 9, 2026Yahoo · 10/8/2026
- Hyperfine Affirms FY2026 Sales Guidance of $20.000M-$22.000M vs $20.163M EstBenzinga · 10/8/2026
- Hyperfine Expands Global Access to Portable Brain MRI Technology Across Key Gulf Cooperation Council Healthcare MarketsYahoo · 9/28/2026
- BTIG Reiterates Buy on Hyperfine, Maintains $2 Price TargetBenzinga · 9/22/2026
- MedtechWOMEN Names Hyperfine CEO Maria Sainz Winner of 2026 Ferolyn Powell Leadership AwardYahoo · 9/16/2026
- Hyperfine Announces Completion of Enrollment in the Contrast PMR Study to Support the Submission to Expand Indications for Use of the Swoop® System with Contrast AgentsYahoo · 9/15/2026
Insider Activity
Insider Actions →- TEISSEYRE THOMAS · August 24, 2026 · Sale7.3K @ $0.854
- HALE BRETT · August 24, 2026 · Sale7.3K @ $0.854
- Wolterman Dan · June 3, 2026 · Grant52.6K
- HALE BRETT · May 26, 2026 · Sale6.0K @ $1.65
- TEISSEYRE THOMAS · May 26, 2026 · Sale6.0K @ $1.65
- Wolterman Dan · May 22, 2026 · Grant157.7K
- Dahldorf John T · May 22, 2026 · Grant157.7K
- Fattori Ruth A · May 22, 2026 · Grant157.7K
- Jonathan M. Rothberg · May 22, 2026 · Grant157.7K
Institutional Ownership
March 31, 2026
- Total shares held
- 13.44M
- Total value held
- $14.50M
- Institutional holders
- 49
- Unknown3.45M
- Unknown1.74M
- Unknown1.32M
- Unknown1.00M
- Unknown955.3K
- Unknown898.7K
- Unknown730.2K
- Unknown574.9K
- Unknown324.1K
- Unknown313.4K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Hyperfine Expands Portable Brain MRI Reach to Gulf Markets
Hyperfine has announced that its portable brain MRI system will now be available in key Gulf Cooperation Council countries, expanding its global footprint. The move follows the company’s recent rollout in other international markets and could increase adoption in the region’s hospitals. BTIG has reiterated a bullish stance, keeping its $2 price target unchanged. These developments highlight growing interest in Hyperfine’s technology.
Hyperfine Expands Portable Brain MRI Reach to Gulf Markets. Hyperfine has announced that its portable brain MRI system will now be available in key Gulf Cooperation Council countries, expanding its global footprint. The move follows the company’s recent rollout in other international markets and could increase adoption in the region’s hospitals. BTIG has reiterated a bullish stance, keeping its $2 price target unchanged. These developments highlight growing interest in Hyperfine’s technology.